the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs

• Status: Completed
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis. The investigators' study will elaborate the clinical significance of CTCs intervented by Traditional Chinese Medicine(TCM) in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Treatments: Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

1. Complete resection was accepted in IIa ~ Ⅲa stage, and the pathological changes could confirmed as non small cell lung cancer patients;

2. Patients receiving chemotherapy for the first time in 6 weeks after surgery;

3. Age from 18 Years to 70 Years;

4. The liver and renal function were normal,and no other disease.

5. Patients compliance is good ang can understand the situation of this study and signed informed consent

Exclusion Criteria:

1. Patients without clear pathological diagnosis;

2. The expected survival period is morn than 6 months;

3. Patients with serious diseases such as heart, liver, kidney and hematopoietic system;

4. Patients with pregnancy or lactation;

5. Persons with a history of less control.